Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC)

Historical Holders from Q1 2014 to Q2 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
RVNC
Shares outstanding
104,661,494
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Teoxane SA 6.2% 0% $32,335,404 6,550,800 0% Teoxane SA 30 Jan 2025
FRANKLIN RESOURCES INC 4.6% $23,617,550 4,784,658 Franklin Resources, Inc. 30 Sep 2024
Palo Alto Investors LP 1.5% $7,955,942 1,611,787 Patrick Lee, MD 30 Sep 2024

Institutional Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (% of par) Investors
2025 Q2 0 $0 -$425,554 0
2025 Q1 86,100 $425,000 -$245,915,234 493.61% 1
2024 Q4 81,615,726 $248,111,500 -$34,278,677 304% 169
2024 Q3 82,514,296 $428,141,597 +$73,554,744 519% 203
2024 Q2 81,380,096 $209,199,026 -$16,428,979 257% 172
2024 Q1 83,044,426 $408,576,667 +$33,183,947 492% 182
2023 Q4 34,201 $300,627 -$201,855 879% 1
2023 Q3 77,685,888 $891,079,390 -$145,567,704 1,147% 181
2023 Q2 81,597,941 $2,065,272,770 +$115,072,091 2,531% 210
2023 Q1 76,516,583 $2,464,233,486 +$117,644,613 3,221% 215
2022 Q4 73,748,021 $1,361,391,547 +$100,535,684 1,846% 186
2022 Q3 67,536,506 $1,821,529,107 +$324,818,754 2,699.99% 175
2022 Q2 55,780,275 $770,923,957 +$8,673,737 1,382% 152
2022 Q1 54,399,919 $1,060,603,136 +$29,983,679 1,950% 146
2021 Q4 52,490,585 $856,706,987 -$86,379,330 1,632% 139
2021 Q3 54,826,840 $1,527,481,962 +$20,185,748 2,786.01% 153
2021 Q2 53,794,598 $1,592,231,549 -$21,386,577 2,964% 156
2021 Q1 54,581,540 $1,525,520,506 +$56,425,874 2,794.99% 145
2020 Q4 52,592,482 $1,490,407,290 +$95,537,202 2,833.99% 145
2020 Q3 49,347,382 $1,242,933,966 -$27,121,551 2,514% 146
2020 Q2 49,867,878 $1,216,503,031 +$35,616,766 2,441.99% 135
2020 Q1 49,293,392 $729,753,856 -$25,443,570 1,480% 120
2019 Q4 50,824,274 $824,868,235 +$129,782,986 1,622.98% 125
2019 Q3 42,605,836 $553,941,602 -$12,407,642 1,300% 104
2019 Q2 43,043,659 $557,396,588 +$27,061,482 1,297% 108
2019 Q1 40,565,324 $639,315,834 +$98,451,099 1,576.01% 104
2018 Q4 31,723,980 $638,582,573 +$17,643,380 2,012.94% 95
2018 Q3 34,009,383 $845,132,934 -$21,938,902 2,485% 107
2018 Q2 31,084,230 $853,299,930 +$18,852,772 2,745.02% 107
2018 Q1 34,209,499 $1,053,625,660 -$32,732,651 3,079.99% 118
2017 Q4 34,942,553 $1,246,690,005 +$167,196,133 3,575% 113
2017 Q3 27,414,652 $754,198,335 -$1,518,505 2,755% 82
2017 Q2 27,519,844 $726,508,386 +$33,692,658 2,639.89% 84
2017 Q1 26,244,438 $545,878,202 +$45,353,932 2,080% 75
2016 Q4 26,079,545 $539,838,722 +$12,164,864 2,070% 79
2016 Q3 28,646,674 $464,359,406 -$1,079,896 1,621% 74
2016 Q2 28,754,017 $391,052,386 +$16,928,575 1,360% 76
2016 Q1 27,202,594 $474,934,380 -$25,985,490 1,746% 82
2015 Q4 27,209,685 $929,575,673 +$189,567,502 3,415.98% 101
2015 Q3 21,644,614 $644,108,702 +$32,787,105 2,976% 76
2015 Q2 20,375,790 $651,623,876 +$15,879,760 3,198% 86
2015 Q1 20,572,529 $426,440,171 +$18,581,352 2,072.98% 69
2014 Q4 19,756,513 $334,667,612 +$8,319,858 1,693.93% 67
2014 Q3 15,656,921 $302,653,761 -$45,141,249 1,933.04% 80
2014 Q2 16,359,430 $556,110,916 +$155,037,820 3,400% 97
2014 Q1 11,832,924 $372,736,175 +$371,917,123 3,150% 65